Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec

Nonparametric Estimation from Incomplete Observations

Edward L. Kaplan, Paul Meier · Journal of the American Statistical Association · 1958 · 39.1K citations

Public Health, Biostatistics, Mathematics +10

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

Timothy P. Hughes, Andreas Hochhaus, Susan Branford et al. · Blood · 2010 · 487 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Assessment of <i>BCR-ABL1</i> Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

David Marín, Amr R. Ibrahim, Claire Lucas et al. · Journal of Clinical Oncology · 2011 · 475 citations

Medicine, Hematology, Oncology +13

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

Benjamin Hanfstein, Marc Müller, Rüdiger Hehlmann et al. · Leukemia · 2012 · 417 citations

Life Sciences, Molecular Biology, Oncology +16

The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia

Lihui Wang, Kevin Pearson, Julia E. Ferguson et al. · British Journal of Haematology · 2003 · 146 citations

Medicine, Hematology, Oncology +14